BCIQ Profiles

Company Profile Report

Lundbeck enters migraine race with $2B takeout of Alder

Lundbeck will add a CGRP inhibitor to its neurology pipeline by buying Alder for just shy of $2 billion, but the Scandinavian pharma will be playing catch-up as eptinezumab will likely be fourth among drugs in its class.

On Monday the companies

Read the full 412 word article

How to gain access

Continue reading with a
two-week free trial.